This article about currently available antiplatelet drugs is part of the Antithrombotic and
Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical …

The article describes the mechanisms of action, pharmacokinetics, and pharmacodynamics
of aspirin, dipyridamole, cilostazol, the thienopyridines, and the glycoprotein IIb/IIIa …

This article discusses platelet active drugs as part of the Seventh American College of Chest
Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based …

Antiplatelet therapy remains the mainstay in preventing aberrant platelet activation in
pathophysiological conditions such as myocardial infarction, ischemia, and stroke. Although …

The role of aspirin and other platelet-active drugs in the treatment and prevention of
atherothrombosis has been reviewed recently by the Sixth American College of Chest …

This chapter focuses on new antithrombotic drugs that are in phase II or III clinical testing.
Development of these new agents was prompted by limitations of existing antiplatelet …

Background This guideline focuses on long-term administration of antithrombotic drugs
designed for primary and secondary prevention of cardiovascular disease, including two …

Thrombosis, an important complication of atherosclerosis and of various medical and
surgical conditions, can be prevented or treated effectively by a variety of pharmacologic …

Abbreviations: ACE trial Acetylsalicylic Acid and Carotid Endarterectomy; ADP adenosine
diphosphate; AMP adenosine monophosphate; CAPRIE study Clopidogrel vs Aspirin in …

This chapter about antithrombotic therapy for coronary artery disease (CAD) is part of the
Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based …